United Therapeutics Management
Management criteria checks 4/4
United Therapeutics' CEO is Martine Rothblatt, appointed in Jan 1996, has a tenure of 30.42 years. total yearly compensation is $18.04M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 1.58% of the company’s shares, worth $366.26M. The average tenure of the management team and the board of directors is 21.9 years and 23.7 years respectively.
Key information
Martine Rothblatt
Chief executive officer
US$18.0m
Total compensation
| CEO salary percentage | 8.56% |
| CEO tenure | 30.4yrs |
| CEO ownership | 1.6% |
| Management average tenure | 21.9yrs |
| Board average tenure | 23.7yrs |
Recent management updates
Recent updates
Narrative Update • Jun 04
UTHR: IPF Lung Data Will Drive Future Pulmonary Franchise Repricing
Analysts have adjusted the United Therapeutics fair value estimate to $665.23 from $644.08 to reflect updated views on revenue growth potential, profitability, and a lower assumed future P/E multiple following a series of recent price target changes and ratings moves across the Street. Analyst Commentary Recent research has focused on how clinical trial outcomes and pricing assumptions could affect United Therapeutics' earnings power and the appropriate P/E multiple used in valuation models.
Narrative Update • May 17
UTHR: Soft Mist Inhaler Shift Will Pressure Pulmonary Hypertension Expectations
Narrative Update The updated analyst price target for United Therapeutics has edged down by $3 to $516, as analysts factor in a mix of slightly lower projected revenue growth, higher expected profit margins, and a reduced future P/E multiple, following a wave of recent target hikes and one trim across the Street. Analyst Commentary Recent research on United Therapeutics is mixed.Narrative Update • Apr 28
UTHR: IPF And Pulmonary Hypertension Data Will Drive Balanced Future Expectations
Analysts lifted their fair value estimate for United Therapeutics to $519 from $471, citing updated assumptions around revenue growth, profit margins, and future P/E multiples. These updates were informed by a wave of higher Street price targets following encouraging IPF and pulmonary hypertension data and the planned soft mist treprostinil inhaler launch.Seeking Alpha • Apr 22
United Therapeutics: The Future Lies With Manufactured Organs
Summary United Therapeutics is rated a long-term Buy, driven by its pioneering efforts in xenotransplantation and organ manufacturing. Current revenue relies heavily on treprostinil-based therapies, but future growth is expected from FDA-approved lab-grown organs by 2030. Patent expirations and competition present near-term risks, yet margins have improved and the company remains well-positioned for transition. Commercial-scale organ facilities and clinical milestones between 2028-2030 are critical catalysts for UTHR's valuation and portfolio transformation. Read the full article on Seeking AlphaNarrative Update • Apr 14
UTHR: IPF Lung Data Will Shape Future Pulmonary Franchise Outlook
Analysts have lifted the implied fair value estimate for United Therapeutics from about $592 to roughly $644, as higher Street price targets supported by more constructive views on Tyvaso, ralinepag and TreSMI, and a slightly richer assumed future P/E multiple, feed into modestly stronger revenue growth and margin assumptions. Analyst Commentary Street research around United Therapeutics has turned more constructive, with several bullish analysts revisiting their models following clinical updates on ralinepag and the TETON-1 study, along with the introduction of the TreSMI soft mist inhaler and management's longer term revenue ambitions.Narrative Update • Mar 31
UTHR: Pulmonary Fibrosis Promise Will Ultimately Fall Short Of Expectations
United Therapeutics' analyst fair value estimate has shifted from $423 to $471 as analysts factor in recent TETON-1 and ralinepag data, updated profit margin assumptions, and a modestly higher future P/E. Analyst Commentary Street research around United Therapeutics has become more focused on the readthrough from TETON-1 in idiopathic pulmonary fibrosis, the Phase 3 ralinepag results in pulmonary arterial hypertension, and the planned soft mist inhaler for treprostinil.Narrative Update • Mar 16
UTHR: IPF And PAH Data Plus New Inhaler Will Shape Outlook
The analyst fair value estimate for United Therapeutics has been raised from $572.00 to $592.25 as analysts factor in higher assumed revenue growth, slightly stronger profit margins, and supportive Street research that highlights upcoming idiopathic pulmonary fibrosis and pulmonary arterial hypertension catalysts, as well as the planned soft mist treprostinil inhaler. Analyst Commentary Recent Street research around United Therapeutics clusters around two big themes, the pulmonary arterial hypertension and idiopathic pulmonary fibrosis pipeline, and the shift toward next generation treprostinil delivery, including the soft mist inhaler.Narrative Update • Mar 02
UTHR: Ralinepag Phase 3 Success And New Inhaler Will Drive Upside
Narrative Update: United Therapeutics (UTHR) The updated analyst price target for United Therapeutics has moved from $531.25 to $572.00. This reflects analysts' higher conviction in ralinepag following stronger than expected Phase 3 data, as well as the potential long term contribution from the planned treprostinil soft mist inhaler program.Narrative Update • Feb 16
UTHR: Organ Manufacturing And Sector M&A Capital Will Support Future Upside
United Therapeutics' analyst price target edges higher to $645 from $600, as analysts point to a slightly higher fair value estimate of about $531 per share and a modestly adjusted future P/E assumption around 14x, even as they flag ongoing sector level capital and M&A crosscurrents. Analyst Commentary Analysts are updating their views on United Therapeutics as they reset expectations for both the company and the broader Biotech sector heading into 2026.Narrative Update • Feb 02
UTHR: Organ Manufacturing Pipeline And Sector M&A Prospects Will Drive Future Upside
Analysts have nudged their price target higher for United Therapeutics, with updated assumptions pointing to a fair value of about $530.84 per share versus roughly $518.25 previously, supported by slightly higher projected revenue growth and a modestly richer future P/E multiple. Analyst Commentary Recent commentary has focused on what United Therapeutics might look like as the Biotech sector heads into 2026 with cautious optimism.
Narrative Update • Jan 19
UTHR: Respiratory Franchise Execution And Xenotransplantation Progress Will Drive Future Upside
Analysts have raised their price target on United Therapeutics to US$645 from US$575, citing stronger expectations for Tyvaso and Yutrepia revenue, higher projected revenue growth and profit margins, and a lower assumed future P/E multiple, even with a slightly higher discount rate. Analyst Commentary Recent Street research on United Therapeutics has leaned positive, with several bullish analysts lifting their price targets and pointing to execution on key respiratory drugs as a central theme.Narrative Update • Jan 05
UTHR: Pulmonary And IPF Pipeline Momentum Will Support Balanced Future Prospects
Analysts have lifted their blended price targets for United Therapeutics into a roughly US$525 to US$587 range, largely reflecting confidence in Tyvaso-driven Q3 revenue momentum, early Yutrepia uptake, and expectations that the broader pulmonary and IPF franchises and partnership optionality can support the company’s long-term earnings profile. Analyst Commentary Street research around United Therapeutics is clustered around higher price targets in the US$525 to US$587 range, with one firm trimming its target slightly while staying on the sidelines.Narrative Update • Dec 15
UTHR: Future Pulmonary Fibrosis Upside Will Prove Overestimated
We are raising our fair value estimate for United Therapeutics to $423 per share from $320.81, as analysts lift price targets following another record Tyvaso quarter, a strong early Yutrepia launch, and growing conviction that pulmonary fibrosis and ex U.S. partnership opportunities can materially accelerate revenue growth and support higher long term margins. Analyst Commentary Street research following the latest quarter has been broadly constructive, with several firms lifting price targets on the back of record Tyvaso performance and a better than expected Yutrepia launch.Narrative Update • Dec 01
UTHR: Resilient Core And Clinical Milestones Will Support Balanced Prospects Ahead
The analyst price target for United Therapeutics has increased by $5 to reflect continued strong Tyvaso performance, a robust IPF opportunity, and a resilient core business, according to analysts. Analyst Commentary Recent updates from Wall Street reflect a dynamic range of sentiment regarding United Therapeutics, with several notable price target adjustments following the latest quarterly results and clinical developments.Narrative Update • Nov 17
UTHR: Record Clinical Data And Expanding Pipeline Will Support Balanced Outlook Ahead
United Therapeutics’ analyst price targets have increased, with the fair value estimate rising from $510.77 to $513.00. Analysts point to strong Tyvaso revenue growth, robust product launches, and long-term opportunities in idiopathic pulmonary fibrosis.Narrative Update • Oct 31
UTHR: Recent Clinical Success Will Drive Expansion Into New Pulmonary Markets
United Therapeutics' analyst price target has increased from approximately $493 to $511, as analysts cite strong Tyvaso revenue growth, robust product launches, and positive trial data. These factors support improved profit expectations and future growth prospects.Narrative Update • Oct 17
Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
The analyst price target for United Therapeutics has increased modestly by approximately $8 to $492.85. Analysts cite greater confidence in the company’s future sales and profit margins following recent positive clinical trial outcomes and updated research coverage.Narrative Update • Oct 03
Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
United Therapeutics' analyst price target has climbed significantly, rising from approximately $467 to nearly $485 per share. Analysts cite robust Phase 3 results for Tyvaso in idiopathic pulmonary fibrosis and a strengthened outlook for future sales growth.Narrative Update • Sep 18
Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
Analysts raised their price target for United Therapeutics to $466.82, citing strong TETON-2 Phase 3 data for Tyvaso in IPF that de-risk future revenue, support peak sales projections, and heighten confidence in market exclusivity and regulatory approvals. Analyst Commentary Bullish analysts raised price targets significantly following strong Phase 3 TETON-2 data for Tyvaso in idiopathic pulmonary fibrosis (IPF), with the drug meeting primary and key secondary endpoints and demonstrating competitive, clinically meaningful efficacy.Analysis Article • Sep 03
United Therapeutics Corporation (NASDAQ:UTHR) Surges 38% Yet Its Low P/E Is No Reason For Excitement
United Therapeutics Corporation ( NASDAQ:UTHR ) shareholders would be excited to see that the share price has had a...Narrative Update • Sep 03
Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
United Therapeutics’ consensus price target has been raised from $380.57 to $399.90, reflecting heightened analyst optimism following positive Phase 3 TETON-2 Tyvaso IPF results that signal a multibillion-dollar sales opportunity and improved revenue outlook despite competitive and litigation risks. Analyst Commentary Bullish analysts increased price targets sharply following "surprisingly positive" Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis (IPF), citing clinically meaningful FVC benefit, strong statistical significance, and a competitive efficacy profile compared to pipeline peers.Analysis Article • Jul 22
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Feb 25
United Therapeutics: A Unique Business With High Margins And Expansion Potential
Summary United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion into IPF, Ralinepag development, xenotransplantation breakthroughs, and international market expansion. Despite risks from patent expirations and legal challenges, UTHR's diversified portfolio and strong financials position it well for sustained growth. Read the full article on Seeking AlphaSeeking Alpha • Nov 14
United Therapeutics: One To Believe In Despite Competitive Threats
Summary United Therapeutics Corporation's stock has surged over 300% since my 2020 “Buy” rating, driven by strong sales of Tyvaso DPI and other PAH treatments. Despite facing generic competition, United has maintained resilience, leveraging strategic litigation and innovative product development to protect and grow its revenue streams. United's future growth hinges on expanding Tyvaso DPI's market and advancing its pipeline, including promising IPF treatments and groundbreaking organ transplant technologies. With over $4 billion in cash and a visionary CEO, UTHR is well-positioned for continued double-digit revenue growth and potential M&A opportunities. Read the full article on Seeking Alpha
New Narrative • Aug 22
Innovative Biotech Products Pave The Way For A Future Revenue Surge And Market Leadership
Advancements in treatments for pulmonary hypertension and fibrosis, and pioneering Xenotransplantation products, promise to lead market growth and address unmet medical needs.Seeking Alpha • Aug 20
United Therapeutics: Economics Support Compounding Ability
Summary United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY'24 earnings show continued growth in sales and earnings, with upsides in its Tyvaso segment. The company has started share buybacks and is on track to reach a $3 billion revenue run rate by FY'25, supporting a valuation of $400/share. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$1b |
| Dec 31 2025 | US$18m | US$2m | US$1b |
| Sep 30 2025 | n/a | n/a | US$1b |
| Jun 30 2025 | n/a | n/a | US$1b |
| Mar 31 2025 | n/a | n/a | US$1b |
| Dec 31 2024 | US$23m | US$2m | US$1b |
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
Compensation vs Market: Martine's total compensation ($USD18.04M) is about average for companies of similar size in the US market ($USD14.80M).
Compensation vs Earnings: Martine's compensation has been consistent with company performance over the past year.
CEO
Martine Rothblatt (71 yo)
30.4yrs
Tenure
US$18,038,972
Compensation
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 30.4yrs | US$18.04m | 1.58% $ 366.3m | |
| President & COO | 10yrs | US$14.39m | 0.050% $ 11.7m | |
| CFO & Treasurer | 13.4yrs | US$8.35m | 0.044% $ 10.3m | |
| Executive VP | 30.4yrs | US$5.53m | 0.11% $ 24.7m | |
| Manager of Investor Relations | no data | no data | no data | |
| Associate Vice President of Human Resources | no data | no data | no data | |
| Executive Vice President of Product Development & Xenotransplantation | no data | no data | no data | |
| Senior VP & Chief Medical Officer | no data | no data | no data |
21.9yrs
Average Tenure
60yo
Average Age
Experienced Management: UTHR's management team is seasoned and experienced (21.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 30.4yrs | US$18.04m | 1.58% $ 366.3m | |
| Independent Director | 24.4yrs | US$463.74k | 0.030% $ 6.9m | |
| Independent Director & Member of the Scientific Advisory Board | 23.8yrs | US$499.13k | 0.0089% $ 2.1m | |
| Member of the Scientific Advisory Board & Independent Director | 24.4yrs | US$484.78k | 0.0041% $ 957.8k | |
| Independent Vice Chairman & Lead Independent Director | 23.7yrs | US$541.31k | 0.0061% $ 1.4m | |
| Independent Director | 22.9yrs | US$508.03k | 0.0099% $ 2.3m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 24.4yrs | US$483.03k | 0.051% $ 11.8m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 11yrs | US$476.40k | 0.010% $ 2.3m | |
| Independent Director | 17.2yrs | US$501.40k | 0.048% $ 11.3m | |
| Independent Director | 7.7yrs | US$493.74k | 0.012% $ 2.8m |
23.7yrs
Average Tenure
74yo
Average Age
Experienced Board: UTHR's board of directors are seasoned and experienced ( 23.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 16:22 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
United Therapeutics Corporation is covered by 34 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| James Birchenough | Barclays |
| Derek Taller | Benchmark Company |